In his weekly clinical update, Dr. Griffin discusses the White House COVID adviser calling on doctors to combat a vacuum of medical information, adeno-associated virus type 2 in US children with acute severe hepatitis, genomic investigations of unexplained acute hepatitis in children, surveillance of SARS-CoV-2 at the Huanan seafood market, vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Canada, effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5–17, prevalence and characteristics associated with post–COVID-19 condition among non-hospitalized adolescents and young adults, within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals, live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters, Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2, COVID-19 convalescent plasma utilization in the United States, FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19, anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO), anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19, triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients, and the breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of long COVID symptoms.

Click arrow to play Download TWiV 998 (26 MB .mp3, 43 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• White House COVID adviser calls on doctors to combat medical information (STAT) 2:10
• Adeno-associated virus type 2 in US children with acute severe hepatitis (Nature) 4:48
• Genomic investigations of unexplained acute hepatitis in children (Nature) 7:06
• Surveillance of SARS-CoV-2 at the Huanan Seafood Market (ChinaXiv) 12:52
• Vaccine effectiveness against hospitalization among pediatric SARS-CoV-2 cases (PLOS) 16:51
• Effectiveness of BNT162b2 after extending the series dosing interval in children (Nature) 18:50
• Prevalence and characteristics associated with post–COVID-19 condition (JAMA) 21:32
• Within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals (Nature) 24:30
• Replication-competent-attenuated vaccine sCPD9 elicits immunity to SARS-CoV-2 variants (Nature) 27:32
• Fc-γR antibody functions needed for SARS-CoV-2 variant protection via vaccination (Nature) 30:36
• COVID-19 convalescent plasma utilization in the United States (CID) 34:50
• FDA authorizes Gohibic injection for the treatment of COVID-19  (FDA) 37:48
• IFX-1 antibody vs. supportive care for severe COVID-19 patients (Lancet)38:07
• Vilobelimab therapy for COVID-19 critically ill patients on mechanical ventilation (Lancet) 38:24
• Triple combo therapy for relapsed SARS-CoV-2 in immunocompromised patients with antivirals and antibodies (CID) 39:59
• Neutralizing antibody response breadth to SARS-CoV-2 tied to Long COVID presence (medRxiv) 41:41
• Neurological Long COVID pathogenesis and potential therapies (Journal Cells) 45:08
• Contribute to our ASTMH fundraiser at PWB 46:29
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 998 46:54
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.

Click arrow to play Download TWiV 994 (26 MB .mp3, 43 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• cVDPV2 detections in Burundi and the DRC (PGEI) 4:52
• Novel oral polio vaccine type 2 story (The Lancet) 6:59
• Prior COVID-19 infection associated with risk of diagnosed erectile dysfunction (IJIR) 8:17
• Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection (BMJ) 13:37
• Protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals (The Lancet) 15:00
• Effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths (The Lancet) 25:30
• Projected COVID-19 mortality reduction from Paxlovid rollout (JAMA)
• SARS-CoV-2 mRNA vaccines decouple anti-viral immunity (Nature) 30:50
• Contribute to our ASTMH fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 994 36:15
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

In his weekly clinical update, Dr. Griffin discusses clearance of longstanding, immune-deficiency-associated, vaccine-derived poliovirus infection following remdesivir therapy for chronic SARS-CoV-2 infection, SARS-CoV-2 exposure in New York City rats, clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea, exhaled breath aerosol shedding of SARS-CoV-2 variants, outpatient treatment of COVID-19 and the development of long COVID over 10 months, Nirmatrelvir and the risk of post-acute sequelae of COVID-19, assessment of the risk of venous thromboembolism in nonhospitalized patients with COVID-19, and the optimal duration of systemic corticosteroids in COVID-19 treatment.

Click arrow to play Download TWiV 992 (19 MB .mp3, 32 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Clearance of vaccine-derived poliovirus following remdesivir therapy for SARS-CoV-2 infection (Frontiers) 1:06
• SARS-CoV-2 exposure in Norway rats from New York City (mBio) 3:28
• Clinical characteristics and outcomes of children with SARS-CoV-2 Infection in Korea (JKMS) 6:54
• Exhaled breath aerosol shedding of SARS-CoV-2 variants (CID) 8:37
• Outpatient treatment of COVID-19 and the development of Long COVID (The Lancet)  12:28
• Nirmatrelvir and the risk of post-acute sequelae of COVID-19 (medRxiv) 16:05
• Risk of venous thromboembolism in nonhospitalized patients with COVID-19 (JAMA) 18:14
• Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID) 21:47
• Contribute to our ASTMH fundraiser at PWB 21:43
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 992 24:40
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

In his weekly clinical update Dr. Griffin discusses confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era, the effectiveness of maternal Influenza vaccination in Peru, characteristics and predictors of persistent symptoms post-COVID-19 in children and young people, parental nonadherence to health policy recommendations for prevention of COVID-19 transmission among children, community-onset bacterial coinfection in children critically ill with SARS-CoV-2 infection, bivalent booster effectiveness against severe COVID-19 outcomes in Finland, viral kinetics of sequential SARS-CoV-2 infections, risk of COVID-19 associated pulmonary aspergillosis based on corticosteroid duration in intensive care patients, immunomodulators for severe COVID19 in transplant patients: do they increase the risk of secondary infection, long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population, cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection, one-year adverse outcomes among us adults with Post–COVID-19 condition vs those without COVID-19 in a large commercial insurance database, and long-term gastrointestinal outcomes of COVID-19.

Click arrow to play Download TWiV 990 (26 MB .mp3, 43 min) Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Confronting the evolution and expansion of anti-vaccine activism (The Lancet) 1:17
• Effectiveness of maternal influenza vaccination in Peru (OFID) 2:14
• Characteristics and predictors of persistent symptoms post-COVID-19 (BMJ) 4:11
• Parental nonadherence to health policy recommendations for prevention of COVID-19 (JAMA) 6:11
• Community-onset bacterial coinfection in children ill with SARS-CoV-2 infection (OFID) 7:47
• Bivalent booster effectiveness against severe COVID-19 outcomes (medRxiv) 9:56
• Viral kinetics of sequential SARS-CoV-2 infections (medRxiv) 10:46
• Risk of COVID-19 associated pulmonary aspergillosis based on corticosteroid duration in ICU patients (OFID) 13:50
• Immunomodulators for severe COVID-19 in transplant patients (TID) 15:37
• Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population (eClinicalMedicine) 17:00
• Cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection (BMJ) 18:54
• One year adverse outcomes among US adults with post COVID-19 condition vs those without COVID-19 (JAMA) 19:33
• Long-term gastrointestinal outcomes of COVID-19 (Nature) 21:04
• Contribute to our ASTMH fundraiser at PWB 22:19
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 990 22:51
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]